Skip to main content
OpenTrials
Completed

NCT Number: NCT07001904

Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity

This study aimed to evaluate serum IL-6 levels in plaque psoriasis patients and investigate their correlation with disease severity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Interleukin-6 Disease Severity Plaque Psoriasis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tanta University

Tanta, El-Gharbia, 31527, Egypt

About this study

Psoriasis is a chronic, immune-mediated inflammatory dermatological condition that impacts around 0.2% to 4.8% of the worldwide population.

Interleukin (IL)-6 is a pleiotropic cytokine that regulates immunity, hematopoiesis, and inflammation. It is produced by keratinocytes, endothelial cells, fibroblasts, and immune cells like macrophages and dendritic cells. Increased IL-6 expression has been observed in psoriatic lesions, suggesting its involvement in disease pathogenesis

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age above 18 years.
  • Both sexes.
  • Patients clinically diagnosed with plaque psoriasis.

Exclusion criteria

  • Patients who had received any treatment for psoriasis in the last three months.
  • Patients with other types of psoriasis.
  • Those currently receiving systemic treatment.
  • Individuals with other inflammatory diseases.
  • Pregnant or lactating women.
  • Those using contraceptive pills.
  • Patients with metabolic conditions like diabetes mellitus or thyroid disorders.

Treatment and study plan

Enzyme-linked immunosorbent assay (ELISA)

Other

The enzyme-linked immunosorbent assay (ELISA) was utilized in order to determine the levels of IL-6 in the serum

Primary outcomes

  1. Disease severity

    Time frame: 3 months post-procedure

    Disease severity was assessed using the Psoriasis Area and Severity Index (PASI), categorizing patients into mild (PASI <5), moderate (PASI 5-10), and severe (PASI >10) groups.

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jun 3, 2025
Registry last updated
Jun 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.